{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:42:06Z","timestamp":1767966126119,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2008119"],"award-info":[{"award-number":["APP2008119"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2013565"],"award-info":[{"award-number":["GNT2013565"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple studies have indicated that patients with high body mass index (BMI) may have favourable survival outcomes following treatment with an immune checkpoint inhibitor (ICI). However, this evidence is limited by several factors, notably the minimal evidence from randomised controlled trials (RCTs), the use of categorised BMI with inconsistent cut point definitions, and minimal investigation of contemporary combination ICI therapy. Moreover, whether overweight and obese patients gain a larger benefit from contemporary frontline chemoimmunotherapy in non-small cell lung cancer (NSCLC) is unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This secondary analysis pooled individual patient data from the intention-to-treat population of the IMpower130 and IMpower150 RCTs comparing chemoimmunotherapy versus chemotherapy. Co-primary outcomes were overall survival (OS) and progression-free survival (PFS). The potentially non-linear relationship between BMI and chemoimmunotherapy treatment effect was evaluated using Multivariable Fractional Polynomial Interaction (MFPI). As a sensitivity analysis, chemoimmunotherapy treatment effect (chemoimmunotherapy versus chemotherapy) on survival was also estimated for each BMI subgroup defined by World Health Organisation classification. Exploratory analyses in the respective chemoimmunotherapy and chemotherapy cohort were undertaken to examine the survival outcomes among BMI subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1282 patients were included. From the MFPI analysis, BMI was not significantly associated with chemoimmunotherapy treatment effect with respect to either OS (p\u2009=\u20090.71) or PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.35). This was supported by the sensitivity analyses that demonstrated no significant treatment effect improvement in OS\/PFS among overweight or obese patients compared to normal weight patients (OS: normal BMI HR\u2009=\u20090.74 95% CI 0.59\u20130.93, overweight HR\u2009=\u20090.78 95% CI 0.61\u20131.01, obese HR\u2009=\u20090.84 95% CI 0.59\u20131.20). Exploratory analyses further highlighted that survival outcomes were not significantly different across BMI subgroups in either the chemoimmunotherapy therapy cohort (Median OS: normal BMI 19.9 months, overweight 17.9 months, and obese 19.5 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.7) or the chemotherapy cohort (Median OS: normal 14.1 months, overweight 15.9 months, and obese 16.7 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.7).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There was no association between high BMI (overweight or obese individuals) and enhanced chemoimmunotherapy treatment benefit in front-line treatment of advanced non-squamous NSCLC. This contrasts with previous publications that showed a superior treatment benefit in overweight and obese patients treated with immunotherapy given without chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12132-w","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T14:01:30Z","timestamp":1711375290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Lee X.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos S.","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Shahnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"issue":"43","key":"12132_CR1","doi-asserted-by":"publisher","first-page":"e389950-e","DOI":"10.1200\/EDBK_389950","volume":"43","author":"D O'Reilly","year":"2023","unstructured":"O\u2019Reilly D, Botticella A, Barry S, Cotter S, Donington JS, Le Pechoux C, et al. Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More? Am Soc Clin Oncol educ book. 2023;43(43):e389950\u2013e.","journal-title":"Am Soc Clin Oncol educ book."},{"issue":"5","key":"12132_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JCO.22.02121","volume":"41","author":"DH Owen","year":"2023","unstructured":"Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2. J clin oncol. 2023;41(5):e1\u20139.","journal-title":"J clin oncol."},{"issue":"6382","key":"12132_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (American Association for the Advancement of Science). 2018;359(6382):1350\u20135.","journal-title":"Science (American Association for the Advancement of Science)"},{"issue":"5","key":"12132_CR4","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3390\/ijms22052628","volume":"22","author":"A Indini","year":"2021","unstructured":"Indini A, Rijavec E, Ghidini M, Tomasello G, Cattaneo M, Barbin F, et al. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. Int J Mol Sci. 2021;22(5):2628.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"12132_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","volume":"6","author":"G Kichenadasse","year":"2019","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2019;6(4):512\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"12132_CR6","doi-asserted-by":"publisher","first-page":"e001403","DOI":"10.1136\/jitc-2020-001403","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265 50%: a multicenter study with external validation. J Immunother Cancer. 2020;8(2):e001403.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"12132_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"12132_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000520833","volume":"100","author":"T Herrmann","year":"2022","unstructured":"Herrmann T, Mione C, Montoriol P-F, Molnar I, Ginzac A, Durando X, et al. Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma. Oncology. 2022;100(2):114\u201323.","journal-title":"Oncology"},{"issue":"3","key":"12132_CR9","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/cam4.5152","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Rui M, Lin C, Li Z, Wei D, Han R, et al. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent\/metastatic head and neck squamous cell carcinoma. Cancer Med (Malden, MA). 2023;12(3):2702\u201312.","journal-title":"Cancer Med (Malden, MA)."},{"issue":"1","key":"12132_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12874-022-01516-w","volume":"22","author":"W Sauerbrei","year":"2022","unstructured":"Sauerbrei W, Royston P. Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. BMC Med Res Methodol. 2022;22(1):98.","journal-title":"BMC Med Res Methodol."},{"issue":"3","key":"12132_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0197-2456(82)90005-8","volume":"3","author":"SB Green","year":"1982","unstructured":"Green SB. Patient heterogeneity and the need for randomized clinical trials. Control Clin Trials. 1982;3(3):189\u201398.","journal-title":"Control Clin Trials"},{"issue":"2","key":"12132_CR12","doi-asserted-by":"publisher","first-page":"e004374","DOI":"10.1136\/jitc-2021-004374","volume":"10","author":"A Cortellini","year":"2022","unstructured":"Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall\u2019Olio FG, et al. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. J Immunother Cancer. 2022;10(2):e004374.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"12132_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127\u201341.","journal-title":"Stat Med"},{"issue":"12","key":"12132_CR14","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00262-020-02680-y","volume":"69","author":"H Chen","year":"2020","unstructured":"Chen H, Wang D, Zhong Q, Tao Y, Zhou Y, Shi Y. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2020;69(12):2413\u201324.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"12132_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"24","key":"12132_CR16","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"key":"12132_CR17","unstructured":"World Health Organisation. A healthy lifestyle - WHO recommendations World Health Organisation2010 [updated 6 May. Available from: https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/a-healthy-lifestyle---who-recommendations."},{"issue":"2","key":"12132_CR18","first-page":"230","volume":"9","author":"P Royston","year":"2009","unstructured":"Royston P, Sauerbrei W. Two Techniques for Investigating Interactions between Treatment and Continuous Covariates in Clinical Trials. Stand Genomic Sci. 2009;9(2):230\u201351.","journal-title":"Stand Genomic Sci"},{"issue":"23","key":"12132_CR19","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/sim.6986","volume":"35","author":"GS Collins","year":"2016","unstructured":"Collins GS, Ogundimu EO, Cook JA, Manach YL, Altman DG. Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model. Stat Med. 2016;35(23):4124\u201335.","journal-title":"Stat Med"},{"key":"12132_CR20","first-page":"e072883-e","volume":"379","author":"RD Riley","year":"2022","unstructured":"Riley RD, Cole TJ, Deeks J, Kirkham JJ, Morris J, Perera R, et al. On the 12th Day of Christmas, a Statistician Sent to Me. BMJ (Online). 2022;379:e072883-e.","journal-title":"BMJ (Online)."},{"issue":"7549","key":"12132_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","volume":"332","author":"DG Altman","year":"2006","unstructured":"Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080.","journal-title":"BMJ"},{"issue":"15_suppl","key":"12132_CR22","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2021.39.15_suppl.9001","volume":"39","author":"O Akinboro","year":"2021","unstructured":"Akinboro O, Vallejo JJ, Mishra-Kalyani PS, Larkins EA, Drezner NL, Tang S, et al. Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1\u201349%: FDA pooled analysis. J clin oncol. 2021;39(15_suppl):9001.","journal-title":"J clin oncol."},{"key":"12132_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.lungcan.2016.11.017","volume":"104","author":"VK Lam","year":"2017","unstructured":"Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, Vyfhuis M, et al. Obesity Is Associated With Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Lung cancer (Amsterdam, Netherlands). 2017;104:52\u20137.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"9","key":"12132_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","volume":"18","author":"H Lennon","year":"2016","unstructured":"Lennon H, Sperrin M, Badrick E, Renehan AG. The Obesity Paradox in Cancer: a Review. Curr Oncol Rep. 2016;18(9):56.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"12132_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CMM Prado","year":"2008","unstructured":"Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629.","journal-title":"Lancet Oncol"},{"key":"12132_CR26","doi-asserted-by":"crossref","unstructured":"Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491\u20137.","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"12132_CR27","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.2147\/CMAR.S210958","volume":"11","author":"V Magri","year":"2019","unstructured":"Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, et al. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag Res. 2019;11:8201\u20137.","journal-title":"Cancer Manag Res"},{"issue":"12","key":"12132_CR28","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1001\/jamaoncol.2023.3996","volume":"9","author":"AM Hopkins","year":"2023","unstructured":"Hopkins AM, Modi ND, Abuhelwa AY, Kichenadasse G, Kuderer NM, Lyman GH, et al. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncol. 2023;9(12):1621\u20136.","journal-title":"JAMA Oncol."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12132-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12132-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12132-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T14:03:07Z","timestamp":1711375387000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12132-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12132"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12132-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Secondary analysis of anonymised individual patient data was deemed as minimal risk research by the Southern Adelaide Local Health Network, Officer for Research and Ethics, and was exempted from review. Patient consent is not required for secondary analysis of anonymised clinical study data utilised in the present investigation. All patients provided written informed consent for participating IMpower130 and IMpower150 clinical trials as previously reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required for secondary analysis of anonymised individual patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.X.L, G.K, A.S, and A.M.H have no conflicts of interest to disclose.M.J.S reports investigator-initiated project grants from Pfizer, outside the submitted work.M.A.S reports receiving research grants paid to institution from Genentech, Spectrum, Cullinan, Takeda, Diaachi-Sanyko, Enliven, Beigene, OncoC4, serving on a speakers bureau for AZ, Regeneron, Lilly, Genentech, G1 Therapeutics, Guardant, Janssen, Jazz, Mirati, serving on the steering committee\/DSMB for Beigene, BMS, Genentch, Summit, and serving an advisory role with Beigene, Genentech, Spectrum, Lilly, OncoC4, Gilead, Mirati, outside the submitted work.C.S.K reports serving an advisory board role with AstraZeneca, Merck, Roche, Beigene, Jannsen, Gilead, Takeda, Eisai, and BMS.R.A.M reports investigator-initiated project grants from Pfizer, outside the submitted work.A.R reports investigator initiate grant funding outside of the scope of the current project from AstraZeneca, Boehringer Ingelheim and Pfizer, and declares payment of speakers fees for presentations outside of the scope of the current work from Boehringer Ingelheim and Genentech.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"379"}}